Cutoff FFR Values, What to Do in the “Grey Zone”

Original Title: Significance of Intermediate Values of Fractional Flow Reserve in Patients with Coronary Artery Disease. Reference: Julien Adjedj et al. Circulation. 2016 Jan 5. Epub ahead of print.

The fractional flow reserve (FFR) value of 0.75 has been validated against tests for inducible ischemia, whereas the value 0.80 has been widely accepted to guide the clinical practice. All the same, there is a “grey zone” between 0.76 and 0.85 where deciding for one of the two treatment strategies over the other remains arguable.

The study included all patients with single segment disease and an FFR value within the grey area (0.70 – 0.75 and 0.81 – 0.85) between 1997 and 2013. Primary end point was major adverse cardiovascular events (MACE: death, infarction, and any revascularization) within a 5 year follow up.
During this period, 17380 FFR measurements were carried out; 1459 were found in this grey zone and were analyzed. 449 of these were treated with revascularization and 1010 with medical treatment.

In the grey zone, MACE rate was similar between the medical treatment and revascularization groups (13.9% vs. 11.2% respectively; p=0.3). There was a strong trend towards higher death and infarction rates (9.4 vs. 4.8; p=0.06) and higher all cause death rate (7.5 vs. 3.2; p=0.059) in the medical treatment group.

In patients receiving medical treatment, there was a progressive increase in MACE as FFR decreased (de 0.85 a 0.70) especially for proximal lesions; however, patients receiving revascularization did not show this gradient, but a similar MACE rate in all value strata.

Conclusion
FFR in the “grey zone” still has great prognosis value, especially when it comes to proximal lesions. These data confirm the FFR cutoff value ≤ 0.80 is valid to guide our clinical practice.

More articles by this author

Rolling Stone: Registry of Intravascular Lithotripsy vs Atherectomy Use in Complex Calcified Lesions

Severe coronary calcification represents one of the main challenges in performing percutaneous coronary intervention, both due to the higher risk of stent underexpansion and...

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...